Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BB709
- Development stage
- Preclinical
- Lead developer
- BalinBac Therapeutics
- Modality
- Small Molecules
01
Overview
BB709 is a combination of repurposed, FDA-approved small-molecule compounds being developed by BalinBac Therapeutics for the treatment of COVID-19. As part of BalinBac's BB-700 Series (which spans BB-700 to BB-719), the drug is designed to deliver multiple distinct mechanisms of action to directly combat SARS-CoV-2 replication and associated complications in the lungs. By combining existing generic drugs with established safety profiles, BalinBac aims to accelerate the development timeline. BB709 is currently in IND-enabling and DMPK/safety studies.
- Other names
- BB-700 Series subsetBB700 Series subsetBB 700 Series subset
Beyond the preview
Go deeper on BB709.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BB709.